Capricor Therapeutics (CAPR) Times Interest Earned (2013 - 2017)
Capricor Therapeutics (CAPR) posted quarterly Times Interest Earned of -$59.82 for Q1 2026, up 45.59% year-over-year from -$41.09 in Q1 2025, and up 49.22% quarter-over-quarter from -$117.82 in Q4 2025.
Powered by 
Analysis
Capricor Therapeutics (CAPR) Times Interest Earned (2013 - 2017) Analysis & Trends
Capricor Therapeutics' Times Interest Earned history runs 14 years deep, the most recent figure standing at -$59.82 for Q1 2026.
- In Q1 2026, Times Interest Earned rose 45.59% year-over-year to -$59.82; the TTM figure through Mar 2026 stood at -$290.8 (down 615.18% YoY), while the FY2025 annual figure was -$0.39, up 7.03% from the prior year.
- Times Interest Earned for Q1 2026 stood at -$59.82, up from -$117.82 in the prior quarter.
- The five-year high for Times Interest Earned was $11.37 in Q4 2024, with the low at -$254.82 in Q1 2023.
- The 5-year median for Times Interest Earned is -$1.02 (2024), against an average of -$37.94.
- The sharpest annual moves came in 2024 and 2025: Times Interest Earned soared 429.9% in 2024, then slumped 33136.24% in 2025.
- Capricor Therapeutics' Times Interest Earned stood at -$17.13 in 2022, then jumped by 112.53% to $2.15 in 2023, then jumped by 429.9% to $11.37 in 2024, then plunged by 1136.27% to -$117.82 in 2025, then jumped by 49.22% to -$59.82 in 2026.
- Business Quant data shows CAPR's Times Interest Earned at -$59.82 in Q1 2026, -$117.82 in Q4 2025, and -$0.79 in Q3 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Times Interest Earned (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 117.59 |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | -493.00 |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -21.24 |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 8.18 |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.82 |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 1.42 |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -0.08 |
| 10 | Capricor Therapeutics | 543.30 Mn | 543.30 Mn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2017 | -40.85 |
| Sep 30, 2017 | -24.50 |
| Jun 30, 2017 | -32.02 |
| Mar 31, 2017 | -33.85 |
| Dec 31, 2016 | -28.31 |
| Sep 30, 2016 | -53.06 |
| Jun 30, 2016 | -59.99 |
| Mar 31, 2016 | -63.68 |
| Dec 31, 2015 | -51.66 |
| Sep 30, 2015 | -46.21 |
| Jun 30, 2015 | -49.64 |
| Mar 31, 2015 | -55.36 |
| Dec 31, 2014 | -30.91 |
| Sep 30, 2014 | -24.71 |
| Jun 30, 2014 | -27.06 |
| Mar 31, 2014 | -46.81 |
| Dec 31, 2013 | -94.99 |
| Sep 30, 2013 | -63.98 |
| Jun 30, 2013 | -260.04 |
| Mar 31, 2013 | -385.96 |